Views & Analysis Specialty pharma’s next big opportunity: it’s time for patie... In January 2020, the financial conglomerate Visa
News Spyre deprioritises arthritis drug after Phase 2 results Spyre Therapeutics’ hopes for its anti-TL1A antibody SPY072 in rheumatoid arthritis (RA) have hit a bump in the road.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
